Sixty-six patients from the UK with multiple sclerosis (MS) were enrolled in an initial 5-week, placebo-controlled RCT investigating the use of an oral-mucosal THC/CBD spray (Sativex). This study is an uncontrolled, open-label extension of the initial RCT, where all patients completing the initial RCT (n=64) were eligible to continue on the THC/CBD oral spray, and followed for 2-years. Sixty-three patients entered the open-label study and were followed for the number, frequency, and type of adverse events (primary outcome) as well as patient-reported neuropathic pain, blood work, vital signs, medication compliance and intoxication (secondary outcomes).